Source:http://linkedlifedata.com/resource/pubmed/id/14577915
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
16
|
| pubmed:dateCreated |
2003-10-27
|
| pubmed:abstractText |
Duchenne's muscular dystrophy (DMD) is a lethal muscle disease caused by a lack of dystrophin expression at the sarcolemma of muscle fibers. We investigated retroviral vector delivery of dystrophin in dystrophin-deficient DMD(mdx) (hereafter referred to as mdx) mice via an ex vivo approach using mdx muscle-derived stem cells (MDSCs). We generated a retrovirus carrying a functional human mini-dystrophin (RetroDys3999) and used it to stably transduce mdx MDSCs obtained by the preplate technique (MD3999). These MD3999 cells expressed dystrophin and continued to express stem cell markers, including CD34 and Sca-1. MD3999 cells injected into mdx mouse skeletal muscle were able to deliver dystrophin. Though a relatively low number of dystrophin-positive myofibers was generated within the gastrocnemius muscle, these fibers persisted for up to 24 weeks postinjection. The injection of cells from additional MDSC/Dys3999 clones into mdx skeletal muscle resulted in varying numbers of dystrophin-positive myofibers, suggesting a differential regenerating capacity among the clones. At 2 and 4 weeks postinjection, the infiltration of CD4- and CD8-positive lymphocytes and a variety of cytokines was detected within the injected site. These data suggest that the transplantation of retrovirally transduced mdx MDSCs can enable persistent dystrophin restoration in mdx skeletal muscle; however, the differential regenerating capacity observed among the MDSC/Dys3999 clones and the postinjection immune response are potential challenges facing this technology.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1043-0342
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1535-46
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:14577915-Animals,
pubmed-meshheading:14577915-CD4-Positive T-Lymphocytes,
pubmed-meshheading:14577915-CD8-Positive T-Lymphocytes,
pubmed-meshheading:14577915-Cell Transplantation,
pubmed-meshheading:14577915-Cells, Cultured,
pubmed-meshheading:14577915-Dystrophin,
pubmed-meshheading:14577915-Gene Expression,
pubmed-meshheading:14577915-Gene Therapy,
pubmed-meshheading:14577915-Gene Transfer Techniques,
pubmed-meshheading:14577915-Genetic Vectors,
pubmed-meshheading:14577915-Injections, Intramuscular,
pubmed-meshheading:14577915-Mice,
pubmed-meshheading:14577915-Mice, Inbred mdx,
pubmed-meshheading:14577915-Mice, Transgenic,
pubmed-meshheading:14577915-Muscle, Skeletal,
pubmed-meshheading:14577915-Muscular Dystrophy, Animal,
pubmed-meshheading:14577915-Muscular Dystrophy, Duchenne,
pubmed-meshheading:14577915-Retroviridae,
pubmed-meshheading:14577915-Stem Cell Transplantation,
pubmed-meshheading:14577915-Transplantation, Isogeneic
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Dystrophin delivery in dystrophin-deficient DMDmdx skeletal muscle by isogenic muscle-derived stem cell transplantation.
|
| pubmed:affiliation |
Growth and Development Laboratory, Children's Hospital of Pittsburgh, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|